Table 1.

Clinical Trials of Single Agent Neoadjuvant Immune Therapy

Therapeutic Agent	Patients	Regime	N	Outcomes	Grade ¾ irAEs
IFNα-2b Moschos et al., 2018	stage IIIB/C	IV HDIFN 20 MU/m2 5x/week × 4 weeks → surgery → subcutaneous HDI 10MU/m2 3x/week × 48 weeks	20	cRR – 55% pCR – 15%	25%
Pembrolizumab Huang et al. 2019	Resectable stage IIIB/C/or IV	Pembro 200mg × 1 dose → surgery → pembro × 1 year	29	pCR/near pCR: 30%	7 events

cRR – clinical response rate, pCR – pathologic complete response, HDIFN – high-dose interferon alfa-2b, irAE – immune-related adverse events, pembro - pembrolizumab